CASI Pharmaceuticals, Inc.
CASI
$1.94
$0.22713.27%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 71.38% | 95.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 71.38% | 95.85% | |||
| Cost of Revenue | 170.22% | 96.03% | |||
| Gross Profit | -20.20% | 95.69% | |||
| SG&A Expenses | 12.34% | 2.34% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 61.92% | 17.34% | |||
| Operating Income | -52.80% | 15.37% | |||
| Income Before Tax | -71.17% | -20.55% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -71.17% | -20.55% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -71.17% | -20.55% | |||
| EBIT | -52.80% | 15.37% | |||
| EBITDA | -64.64% | 17.03% | |||
| EPS Basic | -36.69% | -6.56% | |||
| Normalized Basic EPS | -2.71% | 8.56% | |||
| EPS Diluted | -36.82% | -6.56% | |||
| Normalized Diluted EPS | -2.71% | 8.56% | |||
| Average Basic Shares Outstanding | 25.22% | 13.13% | |||
| Average Diluted Shares Outstanding | 25.22% | 13.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||